EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study

Victor S Wang iD, Justin Kosman, Hsiangkuo Yuan, Clinton Lauritsen iD, Stephen Shrewsbury, Sheena K Aurora iD, Mary Hopkins, Stephen Silberstein

Headache: The Journal of Head and Face Pain · 2023

DOI: 10.1111/head.14636 ↗

At a glance

Journal article in Headache: The Journal of Head and Face Pain, 2023. Written by Victor S Wang and 7 co-authors. Institution: Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Major MEDLINE topics: Migraine Disorders, Dihydroergotamine, Cardiovascular Diseases, Vasoconstrictor Agents. Cited 5 times so far (Crossref); 24 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Impel Pharmaceuticals, Inc..

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Dihydroergotamine (DHE), like triptans, is contraindicated in patients with ischemic heart disease or coronary vasospasm. Its true safety, tolerability, and efficacy in patients with cardiovascular risk without ischemic heart disease or coronary vasospasm remain unclear.

Objectives

To assess the safety, tolerability, and effectiveness of repetitive intravenous DHE in patients with cardiovascular risk factors.

Methods

A single‐center, retrospective cohort study was conducted at the Jefferson Headache Center inpatient unit for refractory chronic migraine patients treated with our intravenous DHE protocol between January 1, 2019, and October 15, 2019. We evaluated tolerability and effectiveness outcomes based on atherosclerotic cardiovascular disease 10‐year calculated risk scores, stratified into low (

Subjects

MeSH terms (MEDLINE)

Migraine DisordersDihydroergotamineCardiovascular DiseasesVasoconstrictor AgentsHumansRetrospective StudiesFemaleMaleMiddle AgedAdultHeart Disease Risk FactorsChronic DiseaseAdministration, IntravenousTreatment Outcome

Author keywords

chronic daily headachechronic migrainedihydroergotaminemigrainerefractory headache

Substances

DihydroergotamineVasoconstrictor Agents

Authors and institutions

  • Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Thomas Jefferson University College of Population Health, Philadelphia, Pennsylvania, USA.
  • Jefferson Headache Center, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Impel Pharmaceuticals Inc., Seattle, Washington, USA.

ORCID profiles: Victor S Wang, Clinton Lauritsen, Sheena K Aurora

Funding

  • Impel Pharmaceuticals, Inc.

Cite

APA

Wang, V. S., Kosman, J., Yuan, H., Lauritsen, C., Shrewsbury, S., Aurora, S. K., Hopkins, M., & Silberstein, S. (2023). Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14636

Vancouver

Wang VS, Kosman J, Yuan H, Lauritsen C, Shrewsbury S, Aurora SK, et al. Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study. Headache: The Journal of Head and Face Pain. 2023. doi:10.1111/head.14636

BibTeX
@article{Wang2023,
  author = {Wang, Victor S and Kosman, Justin and Yuan, Hsiangkuo and Lauritsen, Clinton and Shrewsbury, Stephen and Aurora, Sheena K and Hopkins, Mary and Silberstein, Stephen},
  title = {Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2023},
  doi = {10.1111/head.14636}
}
Start for free →